Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 16 May 2017 |
| Genmab Announces Financial Results for the First Quarter of 2017 | 10 May 2017 |
| Genmab Announces European Marketing Authorization for DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma | 28 Apr 2017 |
| Genmab Announces New Phase III Combination Study of Daratumumab in Multiple Myeloma | 28 Apr 2017 |
| Genmab Announces Data to be Presented at 2017 ASCO Annual Meeting | 20 Apr 2017 |